



WILLIS® Intracranial Stent Graft System Received SFDA Approval

Recently, WILLIS® intracranial stent graft system (hereinafter referred to as WILLIS®) received the official certificate of regulatory approval from the People's Republic of China's (the "PRC") State Food and Drug Administration.

Insulin Pump Infusion Set Received Re-registration Certificate

Beijing China, February 6, 2013 -- MicroPort Lifesciences (Beijing) Co., Ltd. received re-registration certificate issued by the State Food and Drug Administration (SFDA, 2013 No. 3660208) for its Insulin Pump Infusion Set. The validity period is through February 5, 2017.

Radial Artery Hemostasis Set Received Re-registration Certificate

Recently, Shanghai MicoPort Medical (Group) Co., Ltd. received re-registration certificate issued by the SFDA for Radial Artery Hemostasis set.

Credit Suisse Research Report on MicroPort's Recent Performance

Recently, Credit Suisse reported on MicroPort's SFDA approval on WILLIS and provided the updated forecast for fiscal year 2013.

Contents

Newsletter

Issue 19
2013-2-28

WILLIS® Intracranial Stent Graft System Received SFDA Approval

Recently, WILLIS® intracranial stent graft system (hereinafter referred to as WILLIS®) received the official certificate of regulatory approval from the People's Republic of China's (the "PRC") State Food and Drug Administration. WILLIS®, researched and developed independently by MicroPort NeuroTech (Shanghai) Co., Ltd. (hereinafter referred to as MicroPort NeuroTech) is first-of-its-kind product in China indicated for the treatment of intracranial aneurysms.

"WILLIS® has superior efficacy and safety features. Furthermore, it provides better treatment option for patients with intracranial aneurysm." said Mr. Zhiyong Xie, General Manager of MicroPort NeuroTech.

WILLIS® intracranial stent graft system is composed of the stent, delivery system, cobalt-based alloy stent and PTFE graft. Intracranial aneurysm is a cerebrovascular disorder in which weakness in the wall of a cerebral artery or vein causes a localized dilation or ballooning of the blood vessel. Its incidence rate is as high as 2% to 4%. Once the aneurysm ruptures, the permanent disability and mortality rate is 40% and 33% respectively. Compared with the traditional method of stent-assisted coil embolization treatment, the procedure of vascular reconstruction using WILLIS® effectively shunt the blood flow and keep it off of the aneurysm wall. The prospective, multi-center, controlled clinical study was held in three centers across the country and 87 patients were enrolled in the program. The 6-month follow-up clinical result from WILLIS® group demonstrated 95% closure rate which is far better than coil embolization treatment. In addition, the clinical application of Cerebral Aneurysms to its Related Vascular MRA Imaging, which based on clinical research of WILLIS® intracranial graft stent, obtained the First Class Award of Science and Technology Progress issued by the Ministry of Education.

"The introduction of WILLIS® into our portfolio of products available for sale in the PRC will further strengthen our position as the leading medical device player in the PRC. In addition, this technology demonstrates MicroPort's commitment to improving patient quality of life through continuous innovation in minimally invasive medicine and underlying corporate philosophy Where the Patient Always Comes First." said Mr. Bo Pen, Chief Marketing Officer of MicroPort and Executive Director of MicroPort NeuroTech.

Back to Top

Insulin Pump Infusion Set Received Re-registration Certificate

Beijing China, February 6, 2013 -- MicroPort Lifesciences (Beijing) Co., Ltd. received re-registration certificate issued by the State Food and Drug Administration (SFDA, 2013 No. 3660208) for its Insulin Pump Infusion Set. The validity period is through February 5, 2017.

The infusion set is a plastic tube connected to reservoir through which insulin passes. It uses special materials includes high-quality raw materials and special casing. The strict manufacturing process and quality control management system ensures the safety of the insulin infusion through the prevention of broken knotting. In addition, the special design with rapid separation and waterproof rubber plug greatly enhanced the users' comfort level. The needle's outer diameter is only 0.36mm which is the thinnest type on the current market. The extremely low profile of the needle causes less pain during the injection and improves patient's comfort level.

Insulin Pumps mimic nature pancreatic insulin delivery by infusing fast acting insulin continuously through infusion set and reservoir to maintain the patients' stable blood sugar throughout the day and night. La Fenice® insulin pump is developed and manufactured entirely by MicroPort Lifesciences. Unlike MDI, a pump automatically delivers a constant rate of insulin around the

501 Newton Rd., ZJ Hi-Tech Park
Shanghai 201203, P. R. China
http://www.microport.com.cn/english

Email：ir@microport.com
Tel: （86）(21) 38954600
Fax: （86）(21) 50801305

clock, and users can easily start and stop additional insulin delivery upon demand. The pump delivers background insulin continuously to cover patients' metabolic need for insulin which is called basal rate. It has four different bolus modes on demand in larger doses to cover a meal or to correct for hyperglycemia bolus. Insulin pump therapy is a fast-growing choice for diabetes management. It offers clinical and lifestyle benefits which leads to significant improvements over injection therapy.

Back to Top

Radial Artery Hemostasis Set Received Re-registration Certificate

Recently, Shanghai MicoPort Medical (Group) Co., Ltd. (hereinafter referred as MicroPort) received re-registration certificate issued by the State Food and Drug Administration (SFDA Category II, 2013 No. 2540303) for Radial Artery Hemostasis set. The validity period is through February 7, 2017.

Radial Artery Hemostasis set is independently developed and manufactured by MicroPort. It is mainly used to stop bleeding after the needle puncture in a minimally invasive surgery such as coronary angiography or percutaneous coronary interventional procedures. The product received its first registration in January 2010. Due to the category change in SFDA for certain products, Radial Artery Hemostasis set has been upgraded to the category II, therefore the additional clinical data pertaining to categorical change was required for receiving re-registration certificate. The upgrade represents the increasing requirement of product manufacturing control, quality management and additional clinical applications for MicroPort's Radial Artery Hemostasis set.

Back to Top

Credit Suisse Research Report on MicroPort's Recent Performance (Excerption)

MicroPort announced that its neurovascular device WILLIS intracranial stent graft system was approved by SFDA (the State Food and Drug Administration of China; the nation's FDA) on 26 February 2013. WILLIS is a first-of-its-kind product in China indicated for the treatment of intracranial aneurysms.

Targets a potential market of RMB 800 Million:

In China, the incidence rate of intracranial aneurysm is around 2-4%. Our preliminary analysis indicates a potential RMB 800 million market for intracranial aneurysms treatment; the barrier to capitalize on this is surgeon training–only ~150 surgeons are capable of doing neurovascular interventional operations in China, according to MicroPort management.

Synergy with APOLLO:

MicroPort launched APOLLO intracranial stent system in 2008 and has achieved ~60% market share with 90%+ gross profit margin. We believe there is significant synergy between WILLIS and APOLLO as they can share the distribution channel and hospital access.

2012 result in-line:

We believe earnings downside from slowing DES revenue growth is built into consensus: 1) our talks with cardiovascular surgeons showed that MicroPort is gaining market share; 2) MicroPort's non-DES products will compensate for the lower profit margin from DES.

Maintain OUTPERFORM:

We expect the price-cut overhang to dissipate after the Beijing tender and 2013 DES sales growth to rebound. We increase 2013/14E EPS by 1.2%/1.6% respectively to factor in the additional revenue from WILLIS®. Our target price of HK$5.50 is based on 18x FY13E EPS, implying 7.7x 2011 P/S, lower than the average of where peers trade.

Back to Top

501 Newton Rd., ZJ Hi-Tech Park
Shanghai 201203, P. R. China
http://www.microport.com.cn/english

Email：ir@microport.com
Tel: （86）(21) 38954600
Fax: （86）(21) 50801305